We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Assessment of Safety and Effectiveness of NovoSorb® BTM in Severe Burns

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04090424
Recruitment Status : Recruiting
First Posted : September 16, 2019
Last Update Posted : January 9, 2023
Biomedical Advanced Research and Development Authority
Information provided by (Responsible Party):
PolyNovo Biomaterials Pty Ltd.

Brief Summary:
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM).

Condition or disease Intervention/treatment Phase
Burns Device: NovoSorb BTM Procedure: Standard of Care Not Applicable

Detailed Description:
This is a multi-center, pivotal study to assess the safety and effectiveness of a new method of treating severe burns using NovoSorb® Biodegradable Temporizing Matrix (BTM). A comparison will be made between burn wounds treated with BTM and the institution's standard of care (SOC).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pivotal Study to Assess the Safety and Effectiveness of NovoSorb® Biodegradable Temporizing Matrix (BTM) in the Treatment of Severe Burn Skin Injuries
Actual Study Start Date : May 19, 2021
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Burns

Arm Intervention/treatment
Experimental: NovoSorb BTM
Application of NovoSorb BTM to study lesions
Device: NovoSorb BTM
NovoSorb BTM comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a nonbiodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.

Active Comparator: Standard of Care
Application of the institution's standard to care to study lesions.
Procedure: Standard of Care
Burn wounds will be treated using the institution's standard of care, e.g. primary skin grafting, cadaveric allograft followed by skin grafting.

Primary Outcome Measures :
  1. Proportion of study lesions in both groups with complete wound closure after skin grafting [ Time Frame: 4 weeks after skin grafting ]
    Assessment of clinical outcome by wound closure

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Provide written informed consent directly or via legal representative prior to any clinical study procedures being performed
  2. Willing to comply with all study procedures and expects to be available for the duration of the study
  3. Male and females ≥ 18 years of age and ≤ 75 years of age
  4. Patients with deep dermal or full thickness burns between 3% and 60%, inclusive, of their total body surface area (TBSA).

    Types of burns include the following:

    • Scalding including from hot water, cooking oil, grease
    • Flame
    • Flash
    • Contact
  5. Subjects who have staged surgical procedures planned e.g., one procedure to excise the burn injury and a later procedure to prepare the wound bed and apply an autologous skin graft.
  6. The minimum total area across all lesions to have NovoSorb® BTM applied is 3% BSA
  7. Females, who are non-pregnant, naturally postmenopausal, or who agree to use effective contraceptive methods throughout the course of the study.

Exclusion Criteria:

  1. Has a known hypersensitivity to polyurethane
  2. Only a non-burn injury has been experienced by the subject including soft-tissue degloving and friction burn/crush, i.e., road rash
  3. Multiple traumas, i.e., significant traumatic injury to a solid organ in addition to skin
  4. Presence of a medical condition with a life expectancy of less than 12 months, such as advanced malignancy
  5. Presence of a medical condition that might interfere with treatment evaluation; or require a change in therapy including but not limited to, significant immune deficiency, or skin or vascular diseases in the area of the wound
  6. For females - has known or suspected pregnancy, planned pregnancy, or during lactation
  7. Has exposure to any other investigational agent within the last 6 months
  8. Has exposure to any other treatment/device that will interfere with NovoSorb® BTM integration
  9. Anticipated inability to perform wound care and follow-up procedures
  10. Anticipates of a level of non-compliance
  11. The use of off-label treatments for full-thickness / deep-dermal burns is not permitted
  12. Clinical signs of wound infection at areas to be potentially treated using NovoSorb® BTM that in the opinion of the investigator may compromise safety and study objectives
  13. The use of NovoSorb® BTM on the face and in the perineum area is not permitted

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04090424

Layout table for location contacts
Contact: Kim Bradbury +1(949) 542-0950 kim.b@polynovo.com

Show Show 20 study locations
Sponsors and Collaborators
PolyNovo Biomaterials Pty Ltd.
Biomedical Advanced Research and Development Authority
Layout table for investigator information
Study Director: Marcus Wagstaff, MBBS, PhD Royal Adelaide Hospital, Adelaide SA 5000. Australia
Additional Information:
Layout table for additonal information
Responsible Party: PolyNovo Biomaterials Pty Ltd.
ClinicalTrials.gov Identifier: NCT04090424    
Other Study ID Numbers: CP-003
First Posted: September 16, 2019    Key Record Dates
Last Update Posted: January 9, 2023
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Wounds and Injuries